|Description||RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an IC50 value of 8.3 ± 1.1 nM. RN983 showed similar activities in the allergic mouse model of asthma. RN983 may be effective as a stand-alone asthma therapy or used in combination with inhaled steroids and β-agonists in severe asthmatics.|
|Synonyms||RN983; RN-983; RN 983. 6-(tert-butyl)-8-fluoro-2-(3-(hydroxymethyl)-4-(1-methyl-5-((5-(1-methylpiperidin-4-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-2-yl)phthalazin-1(2H)-one|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
RN486 is a reversible Bruton's tyrosine kinase (Btk) inhibitor with IC50 value of 4.0 nM.
RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an ...
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the...
CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exqui...
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher ...
Btk inhibitor 1
Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...
AVL-292 benzenesulfonate is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM; >1400-fold selectivity ove...